Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer

Affiliations

¹ School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran avana@mums.ac.ir.
² Mashhad University of Medical Sciences, Mashhad, Iran.
³ Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁴ School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Brighton and Sussex Medical School, Falmer, Brighton, United Kingdom.
⁵ Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA.

Comment

Amir Avan et al. J Clin Oncol. 2015.

. 2015 May 20;33(15):1711-2.

doi: 10.1200/JCO.2014.60.4702. Epub 2015 Apr 13.

¹ School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran avana@mums.ac.ir.
² Mashhad University of Medical Sciences, Mashhad, Iran.
³ Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁴ School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Brighton and Sussex Medical School, Falmer, Brighton, United Kingdom.
⁵ Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA.

No abstract available

Comment in

Reply to a. Avan et Al.
Baselga J, Clark E, Kiermaier A, Swain SM. Baselga J, et al. J Clin Oncol. 2015 May 20;33(15):1712. doi: 10.1200/JCO.2015.60.8398. Epub 2015 Apr 13. J Clin Oncol. 2015. PMID: 25870094 No abstract available.

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Baselga J, Cortés J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. Baselga J, et al. J Clin Oncol. 2014 Nov 20;32(33):3753-61. doi: 10.1200/JCO.2013.54.5384. Epub 2014 Oct 20. J Clin Oncol. 2014. PMID: 25332247 Clinical Trial.